ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.

News Market Reaction – ADCT

-14.13% 6.5x vol

44 alerts

-14.13% Session close to close

+2.1% Peak Tracked

-35.0% Trough Tracked

$571.69M Market Cap

6.5x Rel. Volume

In the Dec 3 session, ADCT declined 14.13%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.1% during that session. Argus tracked a trough of -35.0% from its starting point during tracking. Our momentum scanner triggered 44 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 6.5x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -14.1% in the session following this news. A negative reaction despite this being ...

Analysis

The stock dropped -14.1% in the session following this news. A negative reaction despite this being mainly a scheduling announcement would fit a pattern where ADCT has sometimes moved sharply around LOTIS‑7 events, including a -14.13% move on strong efficacy data. Investors have previously reassessed risk after detailed updates, so expectations versus delivered details matter. Existing financing tools, including the active shelf registration, and the company’s broader capital structure could also weigh on sentiment when volatility picks up.

Key Figures

Webcast date: December 3, 2025 Webcast time: 8:00 a.m. EST Toll-free dial-in: 1-800-836-8184 +1 more

4 metrics

Webcast date December 3, 2025 LOTIS-7 clinical trial update event

Webcast time 8:00 a.m. EST Start time for LOTIS-7 update call

Toll-free dial-in 1-800-836-8184 Participant number for North America and Canada

Archive duration 30 days Availability of archived LOTIS-7 webcast

Historical Context

3 past events · Latest: Dec 03 (Positive)

Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 03	LOTIS-7 data update	Positive	-14.1%	Updated Phase 1b efficacy and safety data for ZYNLONTA plus glofitamab.
Dec 02	Webcast announcement	Neutral	+8.5%	Announcement of LOTIS-7 clinical trial update conference call and webcast.
Dec 01	Inducement grants	Neutral	-1.4%	Routine stock option grants totaling 47,000 shares to new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical and data-related news have produced mixed reactions, including sharp moves both up and down. Notably, the December LOTIS‑7 data update with strong efficacy metrics saw a -14.13% move, showing the stock can sell off even on seemingly positive trial headlines.

Recent Company History

Recent news flow has centered on clinical progress and corporate housekeeping. On Dec 3, 2025, updated LOTIS‑7 Phase 1b data for ZYNLONTA plus glofitamab in r/r DLBCL showed high response rates, yet shares fell 14.13%. A day earlier, the company announced today’s LOTIS‑7 update webcast and the stock rose 8.49%. On Dec 1, 2025, routine inducement option grants of 47,000 shares led to a modest -1.4% move. This backdrop shows investors reacting strongly around LOTIS‑7 communications.

Key Terms

antibody drug conjugates, phase 1b, open-label, bispecific antibody, +1 more

5 terms

antibody drug conjugates medical

"a pioneer in the field of antibody drug conjugates (ADCs), today announced"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

phase 1b medical

"LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

open-label medical

"LOTIS-7 Phase 1b open-label clinical trial evaluating the safety"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

bispecific antibody medical

"in combination with the bispecific antibody glofitamab (COLUMVI®) in patients"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

diffuse large B-cell lymphoma medical

"in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)."

A fast-growing form of blood cancer that starts in white blood cells within the lymphatic system and can spread quickly to other organs. Investors watch it because the need for effective treatments, the size of the patient population, and results from clinical trials or regulatory approvals can significantly affect pharmaceutical and biotech company revenues—think of it like a large, urgent market for new medicines where trial results or approvals can move stock prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host corporate webcast to share updated data on December 3, 2025

LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA^® in combination with the bispecific antibody glofitamab (COLUMVI^®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA^®; future safety and efficacy results of the Phase 2 IIT in MZL and any regulatory or compendia pathways; the Company's ability to grow ZYNLONTA^® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA^® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA^® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS-5 and LOTIS-7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions and trade barriers and potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-provide-update-on-lotis-7-clinical-trial-302630851.html

SOURCE ADC Therapeutics SA

FAQ

When will ADC Therapeutics (ADCT) present the LOTIS-7 update?

ADC Therapeutics will present the LOTIS-7 update on December 3, 2025 at 8:00 a.m. EST via conference call and webcast.

What will ADC Therapeutics (ADCT) discuss about the LOTIS-7 trial?

The company will provide updated data on the Phase 1b LOTIS-7 trial evaluating ZYNLONTA plus glofitamab in r/r DLBCL patients.

How can investors access the ADC Therapeutics (ADCT) webcast for the December 3, 2025 call?

Investors can access the live webcast under "Events and Presentations" at ir.adctherapeutics.com after registering.

What is the participant dial-in number for ADC Therapeutics (ADCT) conference call?

The participant toll-free dial-in for North America and Canada is 1-800-836-8184.

How long will the ADC Therapeutics (ADCT) archived webcast be available after the LOTIS-7 update?

The archived webcast will be available for 30 days following the call.